WO2021141108A1 - 核酸増幅方法 - Google Patents
核酸増幅方法 Download PDFInfo
- Publication number
- WO2021141108A1 WO2021141108A1 PCT/JP2021/000457 JP2021000457W WO2021141108A1 WO 2021141108 A1 WO2021141108 A1 WO 2021141108A1 JP 2021000457 W JP2021000457 W JP 2021000457W WO 2021141108 A1 WO2021141108 A1 WO 2021141108A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- stranded nucleic
- pcr
- multiplex
- binding protein
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 17
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 17
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 17
- 238000007403 mPCR Methods 0.000 claims abstract description 47
- 238000010839 reverse transcription Methods 0.000 claims abstract description 47
- 238000006243 chemical reaction Methods 0.000 claims abstract description 44
- 101710088729 Single-stranded nucleic acid-binding protein Proteins 0.000 claims abstract description 42
- 239000002299 complementary DNA Substances 0.000 claims abstract description 24
- 230000035945 sensitivity Effects 0.000 claims abstract description 13
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 5
- 238000003757 reverse transcription PCR Methods 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 60
- 210000003491 skin Anatomy 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 20
- 239000000047 product Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 102100034343 Integrase Human genes 0.000 description 11
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 210000001732 sebaceous gland Anatomy 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000010195 expression analysis Methods 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 210000000106 sweat gland Anatomy 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000013614 RNA sample Substances 0.000 description 4
- 239000011358 absorbing material Substances 0.000 description 4
- 239000005547 deoxyribonucleotide Substances 0.000 description 4
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- -1 rRNA Proteins 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 238000010805 cDNA synthesis kit Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002773 nucleotide Chemical group 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101710085030 Gene 32 protein Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101150104425 T4 gene Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/531—Detection characterised by immobilisation to a surface characterised by the capture moiety being a protein for target oligonucleotides
Definitions
- the present invention relates to a nucleic acid amplification method.
- Multiplex PCR is a method of simultaneously amplifying a plurality of regions from one DNA sample by a PCR reaction using a plurality of primer pairs at the same time.
- Multiplex RT-PCR which combines RNA-to- cDNA reverse transcription (RT) reaction with multiplex PCR, is used for gene expression analysis and genotyping.
- RNA is generally extracted from tissue samples. More recently, as a simpler and non-invasive method for collecting RNA, a method for collecting RNA from skin surface lipids (SSL) has been disclosed (Patent Document 1). RNA contained in SSL is useful as an RNA sample for gene expression analysis and the like. However, since the amount of SSL that can be recovered from one subject is not large and the amount of RNA contained therein is not large, the amount of RNA that can be prepared from the SSL of one subject is very small.
- Non-Patent Document 1 describes that BSA and T4 gene32 protein (T4GP32) improve the PCR response in the presence of an inhibitor.
- Non-Patent Document 2 describes that DMSO and betaine improved the specificity and yield of PCR.
- the yield of RT-PCR products was significantly increased by adding T4GP32 to the RT system during RT-PCR, but T4GP32 was added to the PCR system after RT. However, it is stated that no obvious increase in yield was observed.
- Patent Document 2 in the amplified reverse transcription method (RT-RamDA method) in which cDNA is amplified using RNA as a template, the cDNA is protected from nuclease degradation by binding T4GP32 to the single-stranded cDNA stripped from the template RNA. It has been described that it increases the yield of cDNA.
- Patent Document 1 International Publication No. 2018/0083319
- Patent Document 2 International Publication No. 2016/052619
- Non-Patent Document 1 Appl Environ Microbiol, 1996, 62 (3): 1102-1106
- Non-Patent Document 2 PLOS ONE, 2010, 5 (6): e11024
- Non-Patent Document 3 Appl Environ Microbiol, 1998, 64 (2): 669-677
- the present invention is a nucleic acid amplification method. Synthesizing cDNA from sample RNA by reverse transcription; Amplifying the cDNA by multiplex PCR, The reverse transcription and the multiplex PCR are performed in the presence of a single-stranded nucleic acid-binding protein, wherein the single-stranded nucleic acid-binding protein is T4GP32 or a variant thereof. Provide a method.
- the present invention relates to a method for amplifying nucleic acids from RNA with high sensitivity and high yield.
- the present inventors have found that high yield can be achieved even from a small amount of RNA sample by performing both RT and PCR reactions in multiplex RT-PCR in the presence of T4GP32.
- the present invention improves the sensitivity and yield of multiplex RT-PCR.
- the method of the present invention enables efficient amplification and analysis of trace RNA samples such as SSL-derived RNA.
- the present invention improves the sensitivity, accuracy, and efficiency of analysis using RNA samples (eg, gene analysis, diagnosis, etc.).
- the present invention provides a method for amplifying nucleic acid from RNA.
- the method comprises synthesizing cDNA from sample RNA by reverse transcription and amplifying the cDNA by multiplex PCR.
- the sample RNA can be extracted from animals, plants, microorganisms, viruses, etc. by ordinary means.
- a phenol / chloroform method for the extraction of the RNA, a phenol / chloroform method, an AGPC (acid reagent-phenol-chromol-chromoform extraction) method, or a modified method thereof, a method using a special magnetic particle coated with silica, Solid Phase Reversible Immunobi.
- a method using magnetic particles a commercially available RNA purification reagent (for example, TRIzol (registered trademark) Reagent, RNeasy (registered trademark), QIAzol (registered trademark), ISOGEN, etc.) can be used.
- the sample RNA is a lipid-derived RNA on the surface of the skin.
- skin surface lipids refers to a fat-soluble fraction existing on the surface of the skin, and is sometimes called sebum.
- SSL mainly contains secretions secreted from exocrine glands such as sebaceous glands in the skin, and is present on the surface of the skin in the form of a thin layer covering the skin surface.
- SSL contains RNA derived from the skin cells of a subject, which can be used for analysis of a living body (Patent Document 1).
- the subject from which the SSL-derived RNA is collected may be an organism having SSL on the skin.
- subjects include mammals, including humans and non-human mammals, preferably humans.
- the subject can be a human or non-human mammal that requires or desires analysis of its nucleic acid.
- the subject can be a human or non-human mammal that requires or desires gene expression analysis in the skin or analysis of the condition of the skin or non-skin sites using nucleic acids.
- examples of the enzyme and other reagents for RT include commercially available reverse transcriptase enzyme and reverse transcriptase kits, such as PrimeScript (registered trademark) Revase Transscriptase series (Takara Bio) and SuperScript (registered trademark) Revase. Examples thereof include the Transscriptase series (Life Technologies Japan Co., Ltd.), and SuperScript (registered trademark) III Reverse Transcriptase and SuperScript (registered trademark) VILO cDNA Synthesis kit (all of which are Life Technologies Japan Co., Ltd.) can be preferably used.
- both the RT reaction and MPCR are performed in the presence of a single-stranded nucleic acid-binding protein.
- the single-stranded nucleic acid-binding protein include T4GP32 (T4 gene 32 protein) and a variant thereof.
- T4GP32 is typically a protein consisting of the amino acid sequence of SEQ ID NO: 1 and binds to single-stranded DNA.
- the variant of T4GP32 include a protein obtained by modifying or mutating an arbitrary amino acid on the amino acid sequence of T4GP32.
- T4GP32 examples include proteins having an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1 and that binds to a single-stranded nucleic acid, preferably single-stranded DNA.
- T4GP32 can be purchased (eg from NEW ENGLAND BioLabs Inc., Sigma-Aldrich, etc.).
- the initial concentration of the single-stranded nucleic acid-binding protein in the reaction solution of RT and MPCR may be preferably 1 ⁇ g / mL or more, more preferably 5 ⁇ g / mL or more, still more preferably 7 ⁇ g / mL or more, on the other hand.
- It may be preferably 100 ⁇ g / mL or less, more preferably 20 ⁇ g / mL or less, further preferably 15 ⁇ g / mL or less, or preferably 1 to 100 ⁇ g / mL, more preferably 5 to 20 ⁇ g / mL. It may be sufficient, and more preferably 7 to 15 ⁇ g / mL.
- the RT and MPCR are preferably carried out in separate reaction systems (2 steps), but may be carried out in 1 reaction system (1 step) in terms of simplicity.
- the single-stranded nucleic acid-binding protein used for RT can be used as it is for MPCR.
- Purification of the product obtained by the MPCR is preferably performed by size separation of the reaction product.
- size separation By size separation, the PCR product of interest can be separated from the primers and other impurities contained in the MPCR reaction solution.
- DNA size separation can be performed by, for example, a size separation column, a size separation chip, magnetic beads that can be used for size separation, or the like.
- Preferred examples of magnetic beads that can be used for size separation include Solid Phase Reversible Imaging (SPRI) magnetic beads such as Aple XP.
- SPRI Solid Phase Reversible Imaging
- the molecular size of the DNA adsorbed on the magnetic beads changes.
- the purified PCR product may be subjected to further processing necessary for subsequent analysis.
- the purified PCR product can be prepared into a suitable buffer solution, the PCR primer region contained in the PCR-amplified DNA can be cleaved, or the amplified DNA can be obtained. Further adapter sequences may be added.
- the purified PCR product is prepared into a buffer solution, the PCR primer sequence is removed and adapter ligation is performed on the amplified DNA, and the obtained reaction product is amplified as necessary for various analyzes.
- a library can be prepared.
- VILO RT Reaction Mix 5 ⁇ VILO RT Reaction Mix, which is attached to SuperScript (registered trademark) VILO cDNA Synthesis kit (Life Technologies Japan Co., Ltd.), and Ion AmpliSeq Transcriptome Human GeneK Life (Life Technologies Japan Co., Ltd.) Life Technologies Co., Ltd. It can be performed according to the protocol attached to each kit by using 5 ⁇ Ion CompliSeq HiFi Mix and Ion Ampliseq Transcriptome Human Gene Expression Core Panel attached to.
- the nucleic acid amplification method according to the present invention can be applied to various analyzes or diagnoses using RNA.
- the methods of the invention include any analysis to which multiplex PCR can be applied, such as gene expression analysis, transcriptome analysis, subject functional analysis, disease diagnosis, efficacy of the drug administered to the subject. It can be used for comprehensive gene analysis such as evaluation or expression analysis targeting a specific gene.
- Nucleic acid amplification method Synthesizing cDNA from sample RNA by reverse transcription; Amplifying the cDNA by multiplex PCR, The reverse transcription and the multiplex PCR are performed in the presence of a single-stranded nucleic acid-binding protein, wherein the single-stranded nucleic acid-binding protein is T4GP32 or a variant thereof.
- Method Preferably, the T4GP32 or a variant thereof is a protein consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identical to the sequence and binding to a single-stranded nucleic acid [1]. The method described.
- the T4GP32 or a variant thereof is a protein consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that is at least 90% identical to the sequence and binds to a single-stranded nucleic acid [6]. The improver described.
- the reverse transcription is preferably carried out in a reaction solution containing an oligo dT primer, a random primer, or a mixture thereof. More preferably, it is carried out in a reaction solution containing a random primer.
- the single-stranded nucleic acid-binding protein is T4GP32 or a variant thereof, and the improving agent is reverse transcription and Used, added to both reactions of multiplex PCR.
- the T4GP32 or a variant thereof is a protein consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that is at least 90% identical to the sequence and binds to a single-stranded nucleic acid.
- the reverse transcription is preferably carried out in a reaction solution containing an oligo dT primer, a random primer, or a mixture thereof. More preferably, it is carried out in a reaction solution containing a random primer. Use according to [18] or [19]. [21] Preferably, any one of [18] to [20], wherein the single-stranded nucleic acid-binding protein is used for improving the yield of multiplex RT-PCR using lipid-derived RNA on the surface of the skin. Use of description.
- Example 2 Effect of T4GP32 on Reverse Transcription and Multiplex PCR
- the subject was one healthy adult male. Sebum was collected from the entire face of the subject using an oil removal film (5 x 8 cm, made of polypropylene, 3M Japan). RNA was extracted from the oil removal film by the same procedure as in Example 1. Reverse transcription was carried out in the same manner as in Example 1 under the condition that T4GP32 was added (0.0010 w / v%) or not added. For multiplex PCR, T4GP32 (0.0010 w / v%) was added or not added in the same manner as in Example 1, and the PCR product concentration was measured. Relative yields of PCR products relative to controls (reverse transcription and PCR without T4GP32 added) were determined.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
(特許文献2)国際公開公報第2016/052619号
(非特許文献1)Appl Environ Microbiol, 1996, 62(3):1102-1106
(非特許文献2)PLOS ONE, 2010, 5(6):e11024
(非特許文献3)Appl Environ Microbiol, 1998, 64(2):669-677
(非特許文献4)BioTechniques, 2001, 31(1):81-86
サンプルRNAから逆転写によりcDNAを合成すること;及び、
該cDNAをマルチプレックスPCRにより増幅すること、
を含み、該逆転写及び該マルチプレックスPCRが、一本鎖核酸結合タンパク質の存在下で行われ、該一本鎖核酸結合タンパク質が、T4GP32又はその改変体である、
方法を提供する。
また本発明は、一本鎖核酸結合タンパク質を有効成分とする、マルチプレックスRT-PCRの収量改善剤であって、該一本鎖核酸結合タンパク質がT4GP32又はその改変体であり、かつ逆転写及びマルチプレックスPCRの両方の反応液に添加される、改善剤を提供する。
サンプルRNAから逆転写によりcDNAを合成すること;及び、
該cDNAをマルチプレックスPCRにより増幅すること、
を含み、該逆転写及び該マルチプレックスPCRが、一本鎖核酸結合タンパク質の存在下で行われ、該一本鎖核酸結合タンパク質が、T4GP32又はその改変体である、
方法。
〔2〕好ましくは、前記T4GP32又はその改変体が、配列番号1のアミノ酸配列又は当該配列と少なくとも90%配列同一なアミノ酸配列からなり、かつ一本鎖核酸に結合するタンパク質である、〔1〕記載の方法。
〔3〕前記逆転写が、
好ましくは、オリゴdTプライマー、ランダムプライマー、又はそれらの混合物を含む反応液中で行われ、
より好ましくは、ランダムプライマーを含む反応液中で行われる、
〔1〕又は〔2〕記載の方法。
〔4〕好ましくは、前記サンプルRNAが皮膚表上脂質由来RNAである、〔1〕~〔3〕のいずれか1項記載の方法。
〔5〕前記逆転写と前記マルチプレックスPCRの反応液中における前記一本鎖核酸結合タンパク質の初期濃度が、好ましくは1μg/mL以上、より好ましくは5μg/mL以上、さらに好ましくは7μg/mL以上であり、他方、好ましくは100μg/mL以下、より好ましくは20μg/mL以下、さらに好ましくは15μg/mL以下であるか、あるいは、好ましくは1~100μg/mL、より好ましくは5~20μg/mL、さらに好ましくは7~15μg/mLである、〔1〕~〔4〕のいずれか1項記載の方法。
〔7〕好ましくは、前記T4GP32又はその改変体が、配列番号1のアミノ酸配列又は当該配列と少なくとも90%配列同一なアミノ酸配列からなり、かつ一本鎖核酸に結合するタンパク質である、〔6〕記載の改善剤。
〔8〕前記逆転写が
好ましくは、オリゴdTプライマー、ランダムプライマー、又はそれらの混合物を含む反応液中で行われ、
より好ましくは、ランダムプライマーを含む反応液中で行われる、
〔6〕又は〔7〕記載の改善剤。
〔9〕好ましくは、皮膚表上脂質由来RNAを用いたマルチプレックスRT-PCRの収量を改善する、〔6〕~〔8〕のいずれか1項記載の改善剤。
〔10〕前記逆転写及びマルチプレックスPCRの反応液中における前記一本鎖核酸結合タンパク質の初期濃度が、好ましくは1μg/mL以上、より好ましくは5μg/mL以上、さらに好ましくは7μg/mL以上であり、他方、好ましくは100μg/mL以下、より好ましくは20μg/mL以下、さらに好ましくは15μg/mL以下であるか、あるいは、好ましくは1~100μg/mL、より好ましくは5~20μg/mL、さらに好ましくは7~15μg/mLである、〔6〕~〔9〕のいずれか1項記載の改善剤。
〔11〕好ましくは、マルチプレックスRT-PCRの感度及び収量を改善する、〔6〕~〔10〕のいずれか1項記載の改善剤。
〔13〕好ましくは、前記T4GP32又はその改変体が、配列番号1のアミノ酸配列又は当該配列と少なくとも90%配列同一なアミノ酸配列からなり、かつ一本鎖核酸に結合するタンパク質である、〔12〕記載の使用。
〔14〕前記逆転写が
好ましくは、オリゴdTプライマー、ランダムプライマー、又はそれらの混合物を含む反応液中で行われ、
より好ましくは、ランダムプライマーを含む反応液中で行われる、
〔12〕又は〔13〕記載の使用。
〔15〕好ましくは、前記一本鎖核酸結合タンパク質が皮膚表上脂質由来RNAを用いたマルチプレックスRT-PCRの収量改善のために使用される、〔12〕~〔14〕のいずれか1項記載の使用。
〔16〕前記逆転写及びマルチプレックスPCRの反応液中における前記一本鎖核酸結合タンパク質の初期濃度が、好ましくは1μg/mL以上、より好ましくは5μg/mL以上、さらに好ましくは7μg/mL以上であり、他方、好ましくは100μg/mL以下、より好ましくは20μg/mL以下、さらに好ましくは15μg/mL以下であるか、あるいは、好ましくは1~100μg/mL、より好ましくは5~20μg/mL、さらに好ましくは7~15μg/mLである、〔12〕~〔15〕のいずれか1項記載の使用。
〔17〕好ましくは、前記一本鎖核酸結合タンパク質がマルチプレックスRT-PCRの感度及び収量改善のために使用される、〔12〕~〔16〕のいずれか1項記載の使用。
〔19〕好ましくは、前記T4GP32又はその改変体が、配列番号1のアミノ酸配列又は当該配列と少なくとも90%配列同一なアミノ酸配列からなり、かつ一本鎖核酸に結合するタンパク質である、〔18〕記載の使用。
〔20〕前記逆転写が
好ましくは、オリゴdTプライマー、ランダムプライマー、又はそれらの混合物を含む反応液中で行われ、
より好ましくは、ランダムプライマーを含む反応液中で行われる、
〔18〕又は〔19〕記載の使用。
〔21〕好ましくは、前記一本鎖核酸結合タンパク質が皮膚表上脂質由来RNAを用いたマルチプレックスRT-PCRの収量改善のために使用される、〔18〕~〔20〕のいずれか1項記載の使用。
〔22〕前記逆転写及びマルチプレックスPCRの反応液中における前記一本鎖核酸結合タンパク質の初期濃度が、好ましくは1μg/mL以上、より好ましくは5μg/mL以上、さらに好ましくは7μg/mL以上であり、他方、好ましくは100μg/mL以下、より好ましくは20μg/mL以下、さらに好ましくは15μg/mL以下であるか、あるいは、好ましくは1~100μg/mL、より好ましくは5~20μg/mL、さらに好ましくは7~15μg/mLである、〔18〕~〔21〕のいずれか1項記載の使用。
〔23〕好ましくは、前記一本鎖核酸結合タンパク質がマルチプレックスRT-PCRの感度及び収量改善のために使用される、〔18〕~〔22〕のいずれか1項記載の使用。
1)SSLからのRNA抽出
健常な成人女性又は男性それぞれ1名を被験者とした。あぶら取りフィルム(5×8cm、ポリプロピレン製、3Mジャパン)を用いて、被験者の顔全体から皮脂を回収した。皮脂を含む該あぶら取りフィルムは、まとめてガラスバイアルに移し、RNA精製まで-80℃で保存した。該あぶら取りフィルムに含まれるSSL中RNAを精製した。該あぶら取りフィルムを適当な大きさに切断し、QIAzol(登録商標)Lysis Reagent(QIAGEN)を用いて該フィルムからRNAを含む水相を回収した。回収した水相から、RNeasy(登録商標)(QIAGEN)に付属のプロトコルに準じてRNAを抽出した。
抽出されたRNAから、SuperScript(登録商標)VILO cDNA Synthesis kit(ライフテクノロジーズジャパン株式会社)を用いて42℃、30分間逆転写を行い、cDNAを合成した。逆転写反応のプライマーには、キットに付属しているランダムプライマーを使用した。得られたcDNAからマルチプレックスPCRにより、20802遺伝子に由来するDNAを含むライブラリーを調製した。マルチプレックスPCRは、Ion AmpliSeq Transcriptome Human Gene Expression Kit(ライフテクノロジーズジャパン株式会社)を用いて、PCR改善剤と共に[99℃、2分→(99℃、15秒→60℃、16分)×20サイクル→4℃、Hold]の条件で行った。PCR改善剤としては、既報(非特許文献1、2)に従い、BSA(lyophilized powder,essentially IgG-free,low endotoxin,BioReagent,suitable fwor sell culture)(Sigma aldrich、カタログ番号:A2058)、ベタイン塩酸塩(富士フィルム和光純薬株式会社)、及びT4GP32(NEW ENGLAND BioLabs Inc.)を表1記載の濃度で用いた。調製したライブラリーのPCR産物濃度をTapeStation(アジレント・テクノロジー株式会社)とHigh Sensitivity D1000 ScreenTape(アジレント・テクノロジー株式会社)を用いて測定した。対照(PCR改善剤未添加)に対するPCR産物の相対収量を求めた。
PCR改善剤存在下でのPCR産物の相対収量を表1に示す。なお、表1中、BSAとベタインの結果は女性被験者由来のSSL中RNA、T4GP32の結果は男性被験者由来のSSL中RNAを用いた場合の結果である。T4GP32を添加した場合、対照に対するPCR産物の相対収量は1.41に増加した。一方、BSA又はベタインを添加した場合、対照ではPCR産物が検出されたのに対して、PCR産物は検出限界以下に減少した。既報(非特許文献3、4)では、RT後のPCR系にT4GP32を添加しても明らかな収量の増加はみられないことが報告されているが、本発明のような複数領域を対象とするマルチプレックスPCRの場合には、T4GP32の添加が反応の感度及び収量に顕著な効果を奏すると推測された。
1)逆転写及びマルチプレックスPCR
健常な成人男性1名を被験者とした。あぶら取りフィルム(5×8cm、ポリプロピレン製、3Mジャパン)を用いて、被験者の顔全体から皮脂を回収した。該あぶら取りフィルムから実施例1と同様の手順でRNAを抽出した。逆転写は、T4GP32を添加(0.0010w/v%)又は未添加の条件下で実施例1と同様に実施した。マルチプレックスPCRについても、T4GP32(0.0010w/v%)を添加又は未添加の条件下で実施例1と同様に実施し、PCR産物濃度を測定した。対照(逆転写及びPCRでT4GP32未添加)に対するPCR産物の相対収量を求めた。
結果を表2に示す。逆転写のみにT4GP32を添加した場合、及びマルチプレックスPCRのみにT4GP32を添加した場合には、対照に対する相対収量は、それぞれ1.06と1.41であった。これに対し、逆転写とマルチプレックスPCR双方の行程にT4GP32を添加した場合、相対収量は2.19へと顕著に増加した。
Claims (14)
- 核酸増幅方法であって、
サンプルRNAから逆転写によりcDNAを合成すること;及び、
該cDNAをマルチプレックスPCRにより増幅すること、
を含み、該逆転写及び該マルチプレックスPCRが、一本鎖核酸結合タンパク質の存在下で行われ、該一本鎖核酸結合タンパク質が、T4GP32又はその改変体である、
方法。 - 前記T4GP32又はその改変体が、配列番号1のアミノ酸配列又は当該配列と少なくとも90%配列同一なアミノ酸配列からなり、かつ一本鎖核酸に結合するタンパク質である、請求項1記載の方法。
- 前記逆転写反応が、ランダムプライマーを含む反応液中で行われる、請求項1又は2記載の方法。
- 前記サンプルRNAが、皮膚表上脂質由来RNAである、請求項1~3のいずれか1項記載の方法。
- 前記逆転写と前記マルチプレックスPCRの反応液中における前記一本鎖核酸結合タンパク質の初期濃度が1~100μg/mLである、請求項1~4のいずれか1項記載の方法。
- 一本鎖核酸結合タンパク質を有効成分とする、マルチプレックスRT-PCRの収量改善剤であって、該一本鎖核酸結合タンパク質がT4GP32又はその改変体であり、かつ逆転写及びマルチプレックスPCRの両方の反応液に添加される、改善剤。
- 前記T4GP32又はその改変体が、配列番号1のアミノ酸配列又は当該配列と少なくとも90%配列同一なアミノ酸配列からなり、かつ一本鎖核酸に結合するタンパク質である、請求項6記載の改善剤。
- マルチプレックスRT-PCRの感度及び収量を改善する、請求項6又は7記載の改善剤。
- マルチプレックスRT-PCRの収量改善のための一本鎖核酸結合タンパク質の使用であって、該一本鎖核酸結合タンパク質がT4GP32又はその改変体であり、かつ逆転写及びマルチプレックスPCRの両方の反応液に添加される、使用。
- 前記T4GP32又はその改変体が、配列番号1のアミノ酸配列又は当該配列と少なくとも90%配列同一なアミノ酸配列からなり、かつ一本鎖核酸に結合するタンパク質である、請求項9記載の使用。
- 前記一本鎖核酸結合タンパク質が、マルチプレックスRT-PCRの感度及び収量改善のために使用される、請求項9又は10記載の使用。
- マルチプレックスRT-PCRの収量改善剤の製造における一本鎖核酸結合タンパク質の使用であって、該一本鎖核酸結合タンパク質がT4GP32又はその改変体であり、該改善剤が逆転写及びマルチプレックスPCRの両方の反応液に添加される、使用。
- 前記T4GP32又はその改変体が、配列番号1のアミノ酸配列又は当該配列と少なくとも90%配列同一なアミノ酸配列からなり、かつ一本鎖核酸に結合するタンパク質である、請求項12記載の使用。
- 前記一本鎖核酸結合タンパク質が、マルチプレックスRT-PCRの感度及び収量改善のために使用される、請求項12又は13記載の使用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180008491.2A CN114945683A (zh) | 2020-01-10 | 2021-01-08 | 核酸扩增方法 |
KR1020227024002A KR20220115996A (ko) | 2020-01-10 | 2021-01-08 | 핵산 증폭 방법 |
EP21738947.7A EP4089104A4 (en) | 2020-01-10 | 2021-01-08 | NUCLEIC ACID AMPLIFICATION METHOD |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020002506 | 2020-01-10 | ||
JP2020-002506 | 2020-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021141108A1 true WO2021141108A1 (ja) | 2021-07-15 |
Family
ID=76788595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/000457 WO2021141108A1 (ja) | 2020-01-10 | 2021-01-08 | 核酸増幅方法 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4089104A4 (ja) |
JP (1) | JP2021108664A (ja) |
KR (1) | KR20220115996A (ja) |
CN (1) | CN114945683A (ja) |
WO (1) | WO2021141108A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009535053A (ja) * | 2006-05-04 | 2009-10-01 | エーエスエム サイエンティフィック, インコーポレイテッド | レコンビナーゼポリメラーゼ増幅 |
WO2016052619A1 (ja) | 2014-09-30 | 2016-04-07 | 国立研究開発法人理化学研究所 | 核酸の増幅方法 |
WO2018008319A1 (ja) | 2016-07-08 | 2018-01-11 | 花王株式会社 | 核酸試料の調製方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107760770B (zh) * | 2010-06-21 | 2022-05-17 | 生命技术公司 | 用于核酸合成和扩增的组合物、方法和试剂盒 |
-
2021
- 2021-01-08 CN CN202180008491.2A patent/CN114945683A/zh active Pending
- 2021-01-08 WO PCT/JP2021/000457 patent/WO2021141108A1/ja active Application Filing
- 2021-01-08 EP EP21738947.7A patent/EP4089104A4/en active Pending
- 2021-01-08 JP JP2021002015A patent/JP2021108664A/ja active Pending
- 2021-01-08 KR KR1020227024002A patent/KR20220115996A/ko active Search and Examination
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009535053A (ja) * | 2006-05-04 | 2009-10-01 | エーエスエム サイエンティフィック, インコーポレイテッド | レコンビナーゼポリメラーゼ増幅 |
WO2016052619A1 (ja) | 2014-09-30 | 2016-04-07 | 国立研究開発法人理化学研究所 | 核酸の増幅方法 |
WO2018008319A1 (ja) | 2016-07-08 | 2018-01-11 | 花王株式会社 | 核酸試料の調製方法 |
Non-Patent Citations (8)
Title |
---|
APPL ENVIRON MICROBIOL, vol. 62, no. 3, 1996, pages 1102 - 1106 |
APPL ENVIRON MICROBIOL, vol. 64, no. 2, 1998, pages 669 - 677 |
BIOTECHNIQUES, vol. 31, no. 1, 2001, pages 81 - 86 |
CHANDLER, D. P. ET AL.: "Reverse Transcriptase (RT) Inhibition of PCR at Low Concentrations of Template and Its Implications for Quantitative RT- PCR", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 64, no. 2, 1998, pages 669 - 677, XP009141630 * |
PICHÉ CAROLINE, SCHERNTHANER JOHANN P: "Optimization of in Vitro Transcription and Full-Length cDNA Synthesis Using the T4 Bacteriophage Gene 32 Protein", JOURNAL OF BIOMOLECULAR TECHNIQUES, vol. 16, no. 3, 2005, pages 239 - 247, XP055841349 * |
PLOS ONE, vol. 5, no. 6, 2010, pages e11024 |
SCIENCE, vol. 227, 1985, pages 1435 - 41 |
See also references of EP4089104A4 |
Also Published As
Publication number | Publication date |
---|---|
EP4089104A4 (en) | 2024-02-21 |
KR20220115996A (ko) | 2022-08-19 |
CN114945683A (zh) | 2022-08-26 |
EP4089104A1 (en) | 2022-11-16 |
JP2021108664A (ja) | 2021-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240173019A1 (en) | Non-invasive methods for skin sample collection and analysis | |
US20210324480A1 (en) | Non-invasive skin-based detection methods | |
US8465924B2 (en) | Treatment solution for preparing sample solution for nucleic acid amplification reaction and method for detecting nucleic acid by using treatment solution | |
WO2007124072A2 (en) | Methods for capture and detection of micro-rna molecules from the skin by non-invasive tape stripping | |
EP1529841A1 (en) | RNA extraction method, RNA extraction reagent, and method for analyzing biological materials | |
US20080166771A1 (en) | Method and system for detection of nucleic acids | |
US20210071165A1 (en) | Spontaneous Nucleic Acid Purification and Concentration In A Single Step | |
Tesena et al. | Comparison of commercial RNA extraction kits and qPCR master mixes for studying gene expression in small biopsy tissue samples from the equine gastric epithelium | |
TW201114467A (en) | Method, agent, and kit for isolating nucleic acids | |
CN113151398A (zh) | 外泌体中核酸分子的检测方法 | |
WO2021141108A1 (ja) | 核酸増幅方法 | |
WO2020232359A1 (en) | Methods concerning ongoing treatment for cancer | |
WO2022172991A1 (ja) | 皮膚角層由来の核酸試料の調製方法 | |
Dalkılıç et al. | The evaluation and manipulation of different kits for isolation of high-quality RNA from frozen blood | |
WO2021182568A1 (ja) | 皮膚表上脂質由来rnaの調製方法 | |
US10144951B2 (en) | Method and materials to deplete impurities for extraction and purification of nucleic acids from stool | |
US9970053B2 (en) | Washing-free template-ready PCR detection method for RNA | |
WO2012043183A1 (ja) | 糞便中の標的核酸の合成方法 | |
JP2023136356A (ja) | 皮膚表上脂質由来rnaの調製方法 | |
JP7498738B2 (ja) | 皮脂rna情報のデータ均質化方法 | |
KR20220095646A (ko) | 엑소좀 차아집단 액체생검 샘플 제조장치 및 제조방법 | |
JP2009511011A (ja) | Dna採取用ステッカー及びこれからdnaを分離する方法 | |
WO2012014694A1 (ja) | 糞便由来核酸の合成方法 | |
Rahumatullah et al. | Comparison of three extraction methods in the preparation of good yield and quality of total RNA from Toxoplasma gondii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21738947 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 17791709 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20227024002 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021738947 Country of ref document: EP Effective date: 20220810 |